Literature DB >> 11296693

Clinical features and natural history of nonalcoholic steatosis syndromes.

Y Falck-Ytter1, Z M Younossi, G Marchesini, A J McCullough.   

Abstract

Nonalcoholic steatohepatitis, along with other forms of nonalcoholic fatty liver disease, is a chronic liver disease that is attracting increasing significance. It is a clinicopathologic syndrome that was originally described in obese, diabetic females who denied alcohol use but in whom the hepatic histology was consistent with alcoholic hepatitis. This typical patient profile has been expanded and is now recognized to occur even in normal weight males without overt abnormalities in carbohydrate metabolism. Although originally believed to be a benign clinical entity, nonalcoholic steatohepatitis is now recognized as a cause of progressive fibrotic liver disease with adverse clinical sequelae. It is important to emphasize that nonalcoholic steatohepatitis is best considered one type of a larger spectrum of nonalcoholic fatty liver disease that is a consequence of insulin resistance and ranges from fat alone to fat plus inflammation, fat plus ballooning degeneration, and nonalcoholic steatohepatitis, the latter being the most serious form. As with any disease, the clinical importance of nonalcoholic steatohepatitis is related to its prevalence and natural history. Recent studies using different methodologies indicate that in the general population the prevalence of fatty liver and nonalcoholic steatohepatitis is approximately 20% and 3%, respectively. These prevalence rates are increased in certain subpopulations such as obesity and type II diabetes. Of greater concern is the recognition that cirrhosis and liver-related deaths occur in approximately 20% and 8% of these patients, respectively, over a 10-year period. Risk factors for these adverse clinical symptoms include patients older than the age of 45, the presence of diabetes or obesity, an aspartate aminotransferase/alanine aminotransferase ratio > 1 and hepatic histology. However, a number of important unresolved issues must be clarified before the true natural history of this disease can be fully understood.

Entities:  

Mesh:

Year:  2001        PMID: 11296693     DOI: 10.1055/s-2001-12926

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  134 in total

1.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

Authors:  Lei Shen; Jian-Gao Fan; Yan Shao; Min-De Zeng; Jun-Rong Wang; Guo-Hao Luo; Ji-Qiang Li; Si-Yao Chen
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

2.  The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease.

Authors:  Said A Al-Busafi; Peter Ghali; Philip Wong; Javier A Novales-Diaz; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

3.  Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis.

Authors:  Kengo Tomita; Toshiaki Teratani; Hirokazu Yokoyama; Takahiro Suzuki; Rie Irie; Hirotoshi Ebinuma; Hidetsugu Saito; Ryota Hokari; Soichiro Miura; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2011-04-23       Impact factor: 3.199

4.  Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program.

Authors:  Cary H Patt; Hwan Y Yoo; Kourosh Dibadj; John Flynn; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

Review 5.  Ectopic fat accumulation: an important cause of insulin resistance in humans.

Authors:  Hannele Yki-Järvinen
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 6.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

7.  Effect of gadolinium on hepatic fat quantification using multi-echo reconstruction technique with T2* correction and estimation.

Authors:  Mingmei Ge; Jing Zhang; Bing Wu; Zhiqin Liu; Hai Song; Xiangfeng Meng; Xinhuai Wu
Journal:  Eur Radiol       Date:  2015-09-17       Impact factor: 5.315

8.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

Review 9.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

10.  Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients.

Authors:  Matthew Kroh; Rockson Liu; Bipan Chand
Journal:  Surg Endosc       Date:  2007-05-04       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.